We recently came across an article on the AJMC.com website relating to Cannabis & Parkinson's - The AJMC or the Centre for Biosimilars site is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes.
The article on the AJMC website highlights research indicating that cannabis can help alleviate the symptoms of Parkinson's disease, a neurodegenerative disorder that affects movement and can lead to tremors, stiffness, and difficulty with balance and coordination. Parkinson's disease is caused by a loss of dopamine-producing cells in the brain, which results in a lack of control over muscle movements.
Studies have shown that cannabinoids, the active compounds in cannabis, can help alleviate some of the symptoms of Parkinson's disease. THC, the psychoactive component of cannabis, has been found to improve tremors, bradykinesia (slowness of movement), and rigidity in patients with Parkinson's disease. CBD, another cannabinoid found in cannabis, has been found to have anti-inflammatory and neuroprotective properties, which can help alleviate symptoms associated with Parkinson's disease.
While cannabis may not be a cure for Parkinson's disease, it has shown promise as a complementary therapy that can help alleviate symptoms and improve the quality of life for patients. However, it is important to note that the use of cannabis as a treatment for Parkinson's disease is not yet fully understood and more research is needed to better understand the potential benefits and risks.
In conclusion, the article suggests that cannabis has been shown to relieve Parkinson's disease symptoms and may be a valuable complementary therapy for patients suffering from this debilitating condition. However, further research is needed to fully understand the potential benefits and risks associated with using cannabis as a treatment for Parkinson's disease.
The original study was published in Journal of Parkinson’s Disease, and took place in Germany.